NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: TransCode Therapeutics Appoints Dr. Michel Janicot as Senior Development Officer
TL;DR
TransCode Therapeutics gains strategic advantage by appointing Dr. Michel Janicot, leveraging his 35+ years of oncology expertise to accelerate TTX-MC138 and Seviprotimut-L toward clinical trials.
Dr. Janicot will guide TransCode's R&D strategy using his RNA biology and translational medicine expertise to advance oncology programs through preclinical and early clinical development stages.
This appointment strengthens TransCode's mission to defeat metastatic cancer through innovative RNA therapeutics, potentially improving treatment outcomes for cancer patients worldwide.
TransCode brings on a former Janssen leader with deep RNA expertise to advance their nanoparticle platform targeting microRNA-10b, a unique biomarker of cancer metastasis.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has appointed Dr. Michel Janicot as consultant Senior Development Officer to support the advancement of TTX-MC138 and Seviprotimut-L.
Dr. Michel Janicot is the founder of JMi ONConsulting and former senior leader at Rhône-Poulenc Rorer and Janssen, bringing more than 35 years of global oncology drug-development experience with expertise in RNA biology, preclinical strategy, translational medicine, and early clinical development.
TransCode is a clinical-stage oncology company focused on treating metastatic disease through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform.
TTX-MC138 is TransCode's lead therapeutic candidate focused on treating metastatic tumors that overexpress microRNA-10b, which is a unique, well-documented biomarker of metastasis.
Dr. Janicot will guide TransCode's strategic R&D initiatives as the company progresses its investigational oncology programs toward later-stage clinical trials.
The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
TransCode uses its proprietary TTX nanoparticle platform for the intelligent design and effective delivery of RNA therapeutics to overcome the challenges of RNA delivery.
TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to unlock therapeutic access to a variety of novel genetic targets relevant to treating various cancers.
The full press release can be viewed at https://ibn.fm/TAIIy.
Curated from InvestorBrandNetwork (IBN)
